UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU
Changes Represent Biggest Overhaul In UK Clinical Trials Regulation In Over 20 Years
Executive Summary
The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.
You may also be interested in...
£10m Cash Boost For UK Regulator To Speed Up New Drug Approvals
An injection of new money should provide something of a shot in the arm for the UK’s drugs regulator as it deals with post-Brexit realities.
UK Launches Inquiry Into Its Clinical Trials Problems After Pharma Outcry
Stung by criticism from the AstraZeneca and GSK CEOs, the UK government has launched an independent review into commercial clinical trials in the hopes of reversing a steep decline.
UK Kicks Off Landmark Overhaul Of Clinical Trial Framework
The UK regulatory agency, the MHRA, is planning to establish a “world-class sovereign regulatory environment” for clinical trials to support the development of new innovative medicines. In the first of two articles, we look at the MHRA’s proposals to slim down trial approval processes, lighten the safety reporting burden, and introduce greater transparency of trial registration and results.